358 related articles for article (PubMed ID: 31122933)
1. CRISPR/Cas System for Genome Editing: Progress and Prospects as a Therapeutic Tool.
Sahel DK; Mittal A; Chitkara D
J Pharmacol Exp Ther; 2019 Sep; 370(3):725-735. PubMed ID: 31122933
[TBL] [Abstract][Full Text] [Related]
2. Delivery Aspects of CRISPR/Cas for in Vivo Genome Editing.
Wilbie D; Walther J; Mastrobattista E
Acc Chem Res; 2019 Jun; 52(6):1555-1564. PubMed ID: 31099553
[TBL] [Abstract][Full Text] [Related]
3. Exploring the potential of genome editing CRISPR-Cas9 technology.
Singh V; Braddick D; Dhar PK
Gene; 2017 Jan; 599():1-18. PubMed ID: 27836667
[TBL] [Abstract][Full Text] [Related]
4. Delivery of CRISPR/Cas9 for therapeutic genome editing.
Xu X; Wan T; Xin H; Li D; Pan H; Wu J; Ping Y
J Gene Med; 2019 Jul; 21(7):e3107. PubMed ID: 31237055
[TBL] [Abstract][Full Text] [Related]
5. Delivery strategies of the CRISPR-Cas9 gene-editing system for therapeutic applications.
Liu C; Zhang L; Liu H; Cheng K
J Control Release; 2017 Nov; 266():17-26. PubMed ID: 28911805
[TBL] [Abstract][Full Text] [Related]
6. Scaffold-mediated non-viral delivery platform for CRISPR/Cas9-based genome editing.
Chin JS; Chooi WH; Wang H; Ong W; Leong KW; Chew SY
Acta Biomater; 2019 May; 90():60-70. PubMed ID: 30978509
[TBL] [Abstract][Full Text] [Related]
7. Methods for In Vivo CRISPR/Cas Editing of the Adult Murine Retina.
Hung SS; Li F; Wang JH; King AE; Bui BV; Liu GS; Hewitt AW
Methods Mol Biol; 2018; 1715():113-133. PubMed ID: 29188510
[TBL] [Abstract][Full Text] [Related]
8. CRISPR/Cas9-Based Genome Editing for Disease Modeling and Therapy: Challenges and Opportunities for Nonviral Delivery.
Wang HX; Li M; Lee CM; Chakraborty S; Kim HW; Bao G; Leong KW
Chem Rev; 2017 Aug; 117(15):9874-9906. PubMed ID: 28640612
[TBL] [Abstract][Full Text] [Related]
9. Application of the CRISPR/Cas System for Generation of Pathogen-Resistant Plants.
Makarova SS; Khromov AV; Spechenkova NA; Taliansky ME; Kalinina NO
Biochemistry (Mosc); 2018 Dec; 83(12):1552-1562. PubMed ID: 30878030
[TBL] [Abstract][Full Text] [Related]
10. CRISPR-Cas9 delivery strategies and applications: Review and update.
Severi AA; Akbari B
Genesis; 2024 Jun; 62(3):e23598. PubMed ID: 38727638
[TBL] [Abstract][Full Text] [Related]
11. CRISPR-Cas9 gene editing: Delivery aspects and therapeutic potential.
Oude Blenke E; Evers MJ; Mastrobattista E; van der Oost J
J Control Release; 2016 Dec; 244(Pt B):139-148. PubMed ID: 27498021
[TBL] [Abstract][Full Text] [Related]
12. Cationic Polymer-Mediated CRISPR/Cas9 Plasmid Delivery for Genome Editing.
Zhang Z; Wan T; Chen Y; Chen Y; Sun H; Cao T; Songyang Z; Tang G; Wu C; Ping Y; Xu FJ; Huang J
Macromol Rapid Commun; 2019 Mar; 40(5):e1800068. PubMed ID: 29708298
[TBL] [Abstract][Full Text] [Related]
13. CRISPR/Cas9-mediated correction of human genetic disease.
Men K; Duan X; He Z; Yang Y; Yao S; Wei Y
Sci China Life Sci; 2017 May; 60(5):447-457. PubMed ID: 28534256
[TBL] [Abstract][Full Text] [Related]
14. CRISPR/Cas9: targeted genome editing for the treatment of hereditary hearing loss.
Farooq R; Hussain K; Tariq M; Farooq A; Mustafa M
J Appl Genet; 2020 Feb; 61(1):51-65. PubMed ID: 31912450
[TBL] [Abstract][Full Text] [Related]
15. [Research progress in the third-generation genomic editing technology - CRISPR/Cas9].
Zhou Y; Zong Y; Kong X
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2016 Oct; 33(5):713-6. PubMed ID: 27577230
[TBL] [Abstract][Full Text] [Related]
16. Different Methods of Delivering CRISPR/Cas9 Into Cells.
Chandrasekaran AP; Song M; Kim KS; Ramakrishna S
Prog Mol Biol Transl Sci; 2018; 159():157-176. PubMed ID: 30340786
[TBL] [Abstract][Full Text] [Related]
17. [The CRISPR-Cas system: beyond genome editing].
Croteau FR; Rousseau GM; Moineau S
Med Sci (Paris); 2018 Oct; 34(10):813-819. PubMed ID: 30451675
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic application of the CRISPR system: current issues and new prospects.
Lee M; Kim H
Hum Genet; 2019 Jun; 138(6):563-590. PubMed ID: 31115652
[TBL] [Abstract][Full Text] [Related]
19. Strategies for nonviral nanoparticle-based delivery of CRISPR/Cas9 therapeutics.
Chen F; Alphonse M; Liu Q
Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2020 May; 12(3):e1609. PubMed ID: 31797562
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic Applications of CRISPR/Cas for Duchenne Muscular Dystrophy.
Wong TWY; Cohn RD
Curr Gene Ther; 2017; 17(4):301-308. PubMed ID: 29173172
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
